BioNTech (BNTX) stock traded higher on Tuesday after Jefferies upgraded the COVID-19 vaccine maker to Buy, citing the ...

Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

The BioNTech SE ADR BNTX inched 0.06% higher to $123.47 Monday, on what proved to be an all-around great trading session for ...

Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The ...

The latest flu vaccines are now available, and just like the COVID-19 shots, it's recommended to get the flu shot in ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

Jefferies upgraded BioNTech (BNTX) to Buy from Hold with a price target of $150, up from $96. Following Summit Therapeutics' ...

The US Centres for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) have announced a plan to offer ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.